Cellectis S.A. $CLLS Shares Sold by Long Focus Capital Management LLC

Long Focus Capital Management LLC cut its stake in shares of Cellectis S.A. (NASDAQ:CLLS) by 12.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,123,262 shares of the biotechnology company’s stock after selling 594,031 shares during the period. Long Focus Capital Management LLC owned 7.42% of Cellectis worth $11,751,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CLLS. Acadian Asset Management LLC boosted its holdings in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares during the last quarter. Delaney Dennis R purchased a new stake in Cellectis during the third quarter valued at about $68,000. Virtu Financial LLC acquired a new stake in Cellectis during the third quarter worth about $72,000. Millennium Management LLC increased its stake in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Cellectis in the 3rd quarter worth about $633,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CLLS has been the subject of a number of research reports. Clear Str upgraded Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd. Jefferies Financial Group initiated coverage on shares of Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.33.

Cellectis Price Performance

Shares of CLLS stock opened at $3.50 on Tuesday. The firm has a fifty day simple moving average of $3.92 and a 200-day simple moving average of $3.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49. Cellectis S.A. has a twelve month low of $1.10 and a twelve month high of $5.48.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.